VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2015

Jan 15, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2015-01-13

Reporting Person: Silva Paul M (SVP & Corp Controller)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2015-01-13	Common Stock	M	1125	$51.75	Acquired	15312	Direct
2015-01-13	Common Stock	S	425	$120.61	Disposed	14887	Direct
2015-01-13	Common Stock	S	300	$122.28	Disposed	14587	Direct
2015-01-13	Common Stock	S	400	$123.05	Disposed	14187	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2015-01-13	Stock Option (right to buy)	$51.75	M	1125	Disposed	2021-07-12	Common Stock (1125)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	169	Indirect

Footnotes

F1: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1.

F2: Open market sales reported on this line occurred at a weighted average price of $120.61 (range $120.36 to $120.93).

F3: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F4: Open market sales reported on this line occurred at a weighted average price of $122.28 (range $121.83 to $122.62).

F5: Open market sales reported on this line occurred at a weighted average price of $123.05 (range $122.87 to $123.57).

F6: The option vests in 16 quarterly installments from 07/13/2011.